CLOVER BIOPHARMACEUTICALS, LTD. Funds and ETFs Clover Biopharmaceuticals, Ltd.
Equities
2197
KYG2280A1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.345 HKD | -.--% |
|
+4.55% | -44.35% |
| Apr. 12 | Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding | CI |
| Apr. 08 | Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial | MT |
ETFs positioned on Clover Biopharmaceuticals, Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.69% | 4 M€ | -27.92% |
Clover Biopharmaceuticals Ltd is a China-based company mainly engaged in pharmaceutical business. The Company's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The Company's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.35% | 57.21M | |
| -1.74% | 102B | |
| +2.22% | 96.09B | |
| +2.13% | 22.28B | |
| -16.76% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.89% | 16.09B | |
| +5.09% | 13.83B | |
| +33.36% | 11.97B |
- Stock Market
- Equities
- 2197 Stock
- Funds and ETFs Clover Biopharmaceuticals, Ltd.
